Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Opportunities to Manufacture Premium-Priced TKIs for PAH

By GlobalData | April 6, 2016

The Pulmonary Arterial Hypertension (PAH) space, which is currently burdened by significant unmet need, could benefit substantially from a class of drugs known as Tyrosine Kinase Inhibitors (TKIs), which may aid development of a disease-modifying drug, according to an analyst with research and consulting firm GlobalData.

Currently, there are 12 marketed therapies for the treatment of PAH from companies including Actelion, GlaxoSmithKline, United Therapeutics, Bayer, Pfizer, and Gilead Sciences.

Lakshmi Dharmarajan, Ph.D., GlobalData’s Senior Analyst covering Cardiovascular & Metabolic Disorders, says that manufacturing a drug using TKIs could present a significant opportunity for pharmaceutical companies, with the prospect of commanding a high premium over currently existing treatments, which already range in cost from $50,000-$150,000 per year.

Dharmarajan explains: “Previous attempts to develop TKI drugs have met with failure due to the increasing number of concerns regarding the cardiotoxicity of this drug class. For example, Novartis’ cancer blockbuster, imatinib, displayed promising outcomes as a PAH therapy up to Phase III of clinical trials, but severe adverse events caused it to be discontinued.

“Despite these issues, the future prospects of this drug class in PAH treatment continue to be positive. Of course, further research into this class of drugs could be beneficial, since the mechanism of action of TKIs for PAH has already been proven.”

The analyst adds that while all of the current drugs for PAH treatment have the potential to reduce disease progression, none of them are capable of reversing the progression of the disease.

Dharmarajan continues: “TKIs have successfully demonstrated that they can halt cell proliferation, which is a significantly more promising approach than what is currently offered by the late-stage pipeline drugs.

“Indeed, GlobalData believes that focusing on the development of TKI treatments for PAH has the potential not only to produce improved therapies, but also to eventually yield a cure for the disease.”

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50